Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres.
Journal
Nature biomedical engineering
ISSN: 2157-846X
Titre abrégé: Nat Biomed Eng
Pays: England
ID NLM: 101696896
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
02
05
2019
accepted:
09
12
2020
pubmed:
27
1
2021
medline:
18
1
2022
entrez:
26
1
2021
Statut:
ppublish
Résumé
During extracorporeal blood purification, anticoagulants are administered to prevent thrombogenesis. However, haemorrhagic complications owing to near-complete inactivation of blood coagulation and delayed recovery of haemostasis pose serious risks to patients. Here, we show in vitro and in beagle dogs that hydrogel microspheres that adsorb the coagulation factors VIII, IX and XI provide transient blood thinning when placed in the extracorporeal circuit before blood purification. The microspheres inhibited the activities of the coagulation factors by levels (~8-30%) similar to those occurring in mild haemophilia. On its reintroduction into the animal, the purified pseudo-haemophilic blood favoured faster recovery of haemostasis. The transient blood-thinning strategy may increase the safety of clinical blood-purification procedures.
Identifiants
pubmed: 33495638
doi: 10.1038/s41551-020-00673-x
pii: 10.1038/s41551-020-00673-x
doi:
Substances chimiques
Blood Coagulation Factors
0
Hydrogels
0
Factor VIII
9001-27-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1156Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Neri, M. et al. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Critical Care https://doi.org/10.1186/s13054-016-1489-9 (2016).
Eckardt, K.-U. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382, 158–169 (2013).
pubmed: 23727165
doi: 10.1016/S0140-6736(13)60439-0
Zoccali, C. et al. The systemic nature of CKD. Nat. Rev. Nephrol. 13, 344–358 (2017).
pubmed: 28435157
doi: 10.1038/nrneph.2017.52
Carpentier, B., Gautier, A. & Legallais, C. Artificial and bioartificial liver devices: present and future. Gut 58, 1690–1702 (2009).
pubmed: 19923348
doi: 10.1136/gut.2008.175380
Holubek, W. J., Hoffman, R. S., Goldfarb, D. S. & Nelson, L. S. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int. 74, 1327–1334 (2008).
pubmed: 18800032
doi: 10.1038/ki.2008.462
Ronco, C. et al. Renal replacement therapy in acute kidney injury: controversy and consensus. Critical Care https://doi.org/10.1186/s13054-015-0850-8 (2015).
Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008).
pubmed: 18288180
pmcid: 2848509
doi: 10.1038/nature06797
Davenport, A. What are the anticoagulation options for intermittent hemodialysis? Nat. Rev. Nephrol. 7, 499–508 (2011).
pubmed: 21727925
doi: 10.1038/nrneph.2011.88
Caruana, R. J., Raja, R. M., Bush, J. V., Kramer, M. S. & Goldstein, S. J. Heparin free dialysis: comparative data and results in high risk patients. Kidney Int. 31, 1351–1355 (1987).
pubmed: 3613407
doi: 10.1038/ki.1987.149
Levine, M. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334, 677–681 (1996).
pubmed: 8594425
doi: 10.1056/NEJM199603143341101
Parasa, S., Navaneethan, U., Sridhar, A. R. M., Venkatesh, P. G. K. & Olden, K. End-stage renal disease is associated with worse outcomes in hospitalized patients with peptic ulcer bleeding. Gastrointest. Endosc. 77, 609–616 (2013).
pubmed: 23357495
doi: 10.1016/j.gie.2012.11.014
Cheung, J., Yu, A., LaBossiere, J., Zhu, Q. & Fedorak, R. N. Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest. Endosc. 71, 44–49 (2010).
pubmed: 19595311
doi: 10.1016/j.gie.2009.04.014
Rath, C. E., Mailliard, J. A. & Schreiner, G. E. Bleeding tendency in uremia. N. Engl. J. Med. 257, 808–811 (1957).
pubmed: 13477393
doi: 10.1056/NEJM195710242571704
Lu, G. M. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446–44 (2013).
pubmed: 23455714
doi: 10.1038/nm.3102
Crowther, M. A. & Warkentin, T. E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111, 4871–4879 (2008).
pubmed: 18309033
doi: 10.1182/blood-2007-10-120543
Ainle, F. N. et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 114, 1658–1665 (2009).
doi: 10.1182/blood-2009-05-222109
Shenoi, R. A. et al. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.3009427 (2014).
Kindgen-Milles, D., Brandenburger, T. & Dimski, T. Regional citrate anticoagulation for continuous renal replacement therapy. Curr. Opin. Crit. Care 24, 450–454 (2018).
pubmed: 30247214
doi: 10.1097/MCC.0000000000000547
Kreuzer, M. et al. Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. Nephrol. Dialysis Transplant. 25, 3337–3342 (2010).
doi: 10.1093/ndt/gfq225
Evenepoel, P., Maes, B. & Vanwalleghem, J. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am. J. Kidney Dis. 39, 315–323 (2002).
pubmed: 11840372
doi: 10.1053/ajkd.2002.30551
Ji, H. et al. Reinforced-concrete structured hydrogel microspheres with ultrahigh mechanical strength, restricted water uptake, and superior adsorption capacity. ACS Sustain. Chem. Eng. 6, 5950–5958 (2018).
doi: 10.1021/acssuschemeng.7b04323
He, C. et al. Heparin-based and heparin-inspired hydrogels: size-effect, gelation and biomedical applications. J. Mater. Chem. B 7, 1186–1208 (2019).
pubmed: 32255159
doi: 10.1039/C8TB02671H
Paluck, S. J., Nguyen, T. H. & Maynard, H. D. Heparin-mimicking polymers: synthesis and biological applications. Biomacromolecules 17, 3417–3440 (2016).
pubmed: 27739666
pmcid: 5111123
doi: 10.1021/acs.biomac.6b01147
Song, X. et al. Design of carrageenan-based heparin-mimetic gel beads as self-anticoagulant hemoperfusion adsorbents. Biomacromolecules 19, 1966–1978 (2018).
pubmed: 29425448
doi: 10.1021/acs.biomac.7b01724
Zhao, C., Xue, J., Ran, F. & Sun, S. Modification of polyethersulfone membranes—a review of methods. Prog. Mater. Sci. 58, 76–150 (2013).
doi: 10.1016/j.pmatsci.2012.07.002
Niewiarowski, S. & Thomas, D. P. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature 222, 1269–126 (1969).
pubmed: 5789664
doi: 10.1038/2221269a0
Schmaier, A. H. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J. Thrombosis Haemost. 14, 28–39 (2016).
doi: 10.1111/jth.13194
Hong, J., Ekdahl, K. N., Reynolds, H., Larsson, R. & Nilsson, B. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation acid the effect of aspirin. Biomaterials 20, 603–611 (1999).
pubmed: 10208402
doi: 10.1016/S0142-9612(98)00210-5
Flanders, M. M., Crist, R. & Rodgers, G. M. Comparison of five thrombin time reagents. Clin. Chem. 49, 169–172 (2003).
pubmed: 12507975
doi: 10.1373/49.1.169
Kanmangne, F. M., Labarre, D., Serne, H. & Jozefowicz, M. Heparin-like activity of insoluble sulphonated polystyrene resins. Part I: influence of the surface density, nature and binding of substituted anionic groups. Biomaterials 6, 297–302 (1985).
pubmed: 4052545
doi: 10.1016/0142-9612(85)90085-7
Jozefowicz, M. & Jozefonvicz, J. Randomness and biospecificity: random copolymers are capable of biospecific molecular recognition in living systems. Biomaterials 18, 1633–1644 (1997).
pubmed: 9613811
doi: 10.1016/S0142-9612(97)00145-2
Razi, N. et al. Structural and functional properties of heparin analogs obtained by chemical sulfation of Escherichia coli K5 capsular polysaccharide. Biochem. J. 309, 465–472 (1995).
pubmed: 7626010
pmcid: 1135755
doi: 10.1042/bj3090465
Shworak, N. W., Kobayashi, T., de Agostini, A. & Smits, N. C. in Progress in Molecular Biology and Translational Science: Glycosaminoglycans in Development, Health and Disease Vol. 93 (ed. Zhang, L.) 153–178 (2010).
Li, W., Johnson, D. J. D., Esmon, C. T. & Huntington, J. A. Structure of the antithrombin–thrombin–heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat. Struct. Mol. Biol. 11, 857–862 (2004).
pubmed: 15311269
doi: 10.1038/nsmb811
Kalathottukaren, M. T. et al. Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA. Blood 129, 1368–1379 (2017).
pubmed: 28034889
pmcid: 5345737
doi: 10.1182/blood-2016-10-747915
Guglietta, S. et al. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat. Commun. https://doi.org/10.1038/ncomms11037 (2016).
Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34–45 (2013).
pubmed: 23222502
doi: 10.1038/nri3345
Hirsh, J., Anand, S. S., Halperin, J. L. & Fuster, V. Guide to anticoagulant therapy: heparin a statement for healthcare professionals from the American Heart Association. Circulation 103, 2994–3018 (2001).
pubmed: 11413093
doi: 10.1161/01.CIR.103.24.2994
Prince, R. et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood 131, 1360–1371 (2018).
pubmed: 29317453
pmcid: 5865230
doi: 10.1182/blood-2017-09-800326
Peyvandi, F., Garagiola, I. & Young, G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 388, 187–197 (2016).
pubmed: 26897598
doi: 10.1016/S0140-6736(15)01123-X
Hall, J. E. Guyton and Hall Textbook of Medical Physiology (Elsevier Health Sciences, 2015).
Srivastava, A. et al. Guidelines for the management of hemophilia. Haemophilia 19, E1–E47 (2013).
pubmed: 22776238
doi: 10.1111/j.1365-2516.2012.02909.x
Mannucci, P. M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90, 2515–2521 (1997).
pubmed: 9326215
doi: 10.1182/blood.V90.7.2515
White, G. C. et al. Definitions in hemophilia—recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis Haemost. 85, 560–560 (2001).
doi: 10.1055/s-0037-1615621
Gao, A. et al. Linker-free covalent immobilization of heparin, SDF-1 alpha, and CD47 on PTFE surface for antithrombogenicity, endothelialization and anti-inflammation. Biomaterials 140, 201–211 (2017).
pubmed: 28662400
doi: 10.1016/j.biomaterials.2017.06.023
Laville, M. et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int. 86, 1260–1267 (2014).
pubmed: 25007166
doi: 10.1038/ki.2014.225
Biran, R. & Pond, D. Heparin coatings for improving blood compatibility of medical devices. Adv. Drug Deliv. Rev. 112, 12–23 (2017).
pubmed: 28042080
doi: 10.1016/j.addr.2016.12.002
Islam, M. S. et al. Vitamin E-coated and heparin-coated dialyzer membranes for heparin-free hemodialysis: a multicenter, randomized, crossover trial. Am. J. Kidney Dis. 68, 752–762 (2016).
pubmed: 27344212
doi: 10.1053/j.ajkd.2016.05.013
Meng, F. et al. MXene sorbents for removal of urea from dialysate: a step toward the wearable artificial kidney. ACS Nano 12, 10518–10528 (2018).
pubmed: 30257087
doi: 10.1021/acsnano.8b06494
Davenport, A. et al. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 370, 2005–2010 (2007).
pubmed: 18083402
doi: 10.1016/S0140-6736(07)61864-9
Davenport, A. A wearable dialysis device: the first step to continuous therapy. Nat. Rev. Nephrol. 12, 512–514 (2016).
pubmed: 27396699
doi: 10.1038/nrneph.2016.100
Song, X., Wang, R., Zhao, W., Sun, S. & Zhao, C. A facile approach towards amino-coated polyethersulfone particles for the removal of toxins. J. Colloid Interface Sci. 485, 39–50 (2017).
pubmed: 27643469
doi: 10.1016/j.jcis.2016.09.025